Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 18/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | NCS1 | P62166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431949 | 0.85 | CASR (0.71) | CASR | |
| SCHEMBL4207364 | 0.82 | CASR (0.61) | CASRADORA2AADORA1CSNK1DNCS1 | |
| SCHEMBL2430060 | 0.82 | CASR (0.61) | CASRADORA2AADORA1CSNK1DNCS1 | |
| SCHEMBL2430651 | 0.81 | CASR (0.60) | CASRADORA2AADORA1CSNK1DNCS1 | |
| SCHEMBL4037795 | 0.80 | CASR (0.66) | CASRCSNK1DNCS1 | |
| SCHEMBL2429367 | 0.79 | CASR (0.62) | CASRADORA2AADORA1CSNK1DNCS1 | |
| SCHEMBL3644521 | 0.79 | CASR (0.68) | CASRCSNK1DNCS1 | |
| SCHEMBL4038543 | 0.79 | CASR (0.57) | CASRADORA2AADORA1CSNK1DNCS1 | |
| SCHEMBL2434847 | 0.79 | CASR (0.63) | CASR | |
| SCHEMBL4038949 | 0.79 | CASR (0.57) | CASRADORA2AADORA1CSNK1DNCS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | claimed |
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885ADORA2A 321/4885ADORA1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.